Clay B. Siegall
Independent DirectorDr. Clay B. Siegall, Ph.D., serves as a Special Partner at Arsenal Bridge Ventures. Dr. Siegall served as an Independent Chairman since December 13, 2023 until October 28, 2025 at Tourmaline Bio, Inc. Dr. Siegal serves as President, Chief Executive Officer and Chairman at Immunome Inc. since October, 2023. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until October 2023. He serves as an Independent Director at Shattuck Labs, Inc. since March 01, 2024. He Co-Founded Seagen Inc. (formerly known as Seattle Genetics, Inc.). in 1998 and had been its Chief Executive Officer since November 2002 until May 2022 and its President since June 2000 until May 2022. Dr. Siegall had been the Chairman of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since March 2004 until May 2022. He served as Chairman of Umoja BioPharma, Inc. from October 2021 until May 11, 2022. Dr. Siegall had been an Independent Director of Nurix Therapeutics, Inc. since May 28, 2021 until May 15, 2022. He has experience in cancer research and therapeutic drug development. He served as Executive Vice President of Seattle Genetics Inc., from December 1997 to June 2000 and Chief Scientific Officer from December 1997 to November 2002. Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator from February 1991 to January 1995 and as a Principal Scientist from January 1995 to December 1997. He had been Director of Ultragenyx Pharmaceutical Inc. since January 30, 2014 until June 2021. He has been a Director of Seattle Genetics Inc. since December 1997 and served as a Director at Alder Biopharmaceuticals Inc. since 2006 until October 22, 2019. He serves as a Director of Washington Biotechnology and Biomedical Association (WBBA) as well as on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. He served as a Non-Executive Director of Mirna Therapeutics, Inc. since January 30, 2013 until December 31, 2016. From February 1988 to February 1991, he was a Staff Fellow and Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall has authored 67 scientific papers and holds nine patents. He serves on the Editorial Board of three scientific journals and is a Member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation. He was given the Pierce Award in 1995 for his efforts in the field of targeted toxins. In 2002, he was an Ernst & Young Pacific Northwest Entrepreneur of the Year award finalist in the healthcare category. His scientific understanding along with his corporate vision and operational knowledge provide strategic insights to Board of Directors. Dr. Siegall received a Ph. D. in Genetics from George Washington University and a B. S. in Zoology from the University of Maryland.
Positions
- Company NameShattuck Labs, Inc.Stock CodeSTTKPositionIndependent DirectorColleagues
- THTaylor H. SchreiberCo-Founder, CEO & Director
- GSGeorge S. GolumbeskiIndependent Chairman of the Board
- ARAndrew R. NeillChief Financial Officer
- ANArunthathy Nirmalini PanditeChief Medical Officer
- BHBrad HuckabeeVice President of Accounting & SEC reporting
- AAAbhinav A. ShuklaChief Technical Officer
- NWNeil W. GibsonIndependent Director
- HMHelen Marie BoudreauIndependent Director
- CBClay B. SiegallIndependent Director
- Company NameImmunome, Inc.Stock CodeIMNMPositionChairman, President & CEOColleagues
- MRMax RosettChief Financial Officer
- RJRobert J. LechleiderChief Medical Officer
- PTPhilip TsaiChief Technical Officer
- JHJack HigginsChief Scientific Officer
- IBIsaac BarchasLead Independent Director
- JPJames Patrick BoylanIndependent Director
- CACarol A. SchaferIndependent Director
- PWPhilip WagenheimIndependent Director
